Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases.

由人体免疫系统功能障碍引起的疾病（炎性疾病），如类风湿性关节炎、牛皮癣和克罗恩病，在所有文化和社会中都引起疾病，并给卫生保健提供者带来经济压力。 目前的治疗依赖于阻断体内炎症介质的生物药物或抗炎药等药物;这两种治疗方法都可能有严重的副作用。 cpn 10抑制身体的炎症反应，同时保持免疫功能，以对抗感染。 该项目旨在开发基于Cpn 10的新型、安全、有效的生物药物，用于治疗各种慢性炎症性疾病和自身免疫性疾病。

Diseases caused by malfunctioning of the body's immune system (inflammatory diseases) such as rheumatoid arthritis, psoriasis and Crohn's disease cause illness in all cultures and societies, and impose financial strain on health care providers. Current treatment relies on biopharmaceuticals that block inflammatory mediators in the body or with pharmaceuticals such as anti-inflammatory drugs; both these treatments may have serious side effects. Cpn10 suppresses the body's inflammatory response while maintaining immune function to combat infections. The project seeks to develop new, safe and effective biopharmaceuticals based on Cpn10 for the treatment of a variety of chronic inflammatory diseases and autoimmune disorders.